A simple and reproducible method for the measurement of serum
The intravascular aggregation of neutrophils has been implicated in the pathogenesis of several diseases, such as adult respiratory distress syndrome,' haemodialysis induced respiratory distress,2 and neutropenia associated with cardiopulmonary bypass.3 Neutrophil aggregation causes vascular injury in animal models in vivo.4 5 The standard method for measuring neutrophil aggregation, which involves the use of a platelet aggregometer, is adequate for studying the effects of purified complement components and N-formyl-methionyl-leucyl-phenylalanine.2 6 This assay has been found to be insensitive, however, for measuring serum neutrophil aggregating activity,7 unless the aggregation response is augmented by cytochalasin B.'
The aim of this study was to develop a simple, reproducible assay for the effect of human sera on neutrophil aggregation, and to use this assay for studies of neutrophil behaviour in rheumatic disorders. As previously,9 we chose the term 'clustering' to describe microscopic cellular aggregates.
Materials and methods

GRANULOCYTE PREPARATION
Heparinised venous blood from healthy members of the clinical staff was centrifuged at 200 g for 10 minutes. The pellet was kept and the supernatant centrifuged again at 1000 g. This pellet containing platelets was discarded and the first pellet resuspended in the supernatant. This was subsequently allowed to form a sediment for 45 minutes at room temperature with an equal volume of 2% dextran T-500, and the leucocyte rich supernatant was withdrawn. This was layered on top of an Isopaque-Ficoll mixture and centrifuged at 1350 g for 15 minutes. The granulocyte pellet was resuspended in the original serum-dextran mixture. After lysis of erythrocytes with 0-87% ammonium chloride and centrifugation the granulocytes were washed twice and resuspended in Hanks's balanced salt solution, containing 0-5% human serum albumin, until use. This produced a granulocyte preparation that was >99% free of mononuclear cells and platelets.
CLUSTERING ASSAY Serum (40 iil) was layered on an object glass at 37°C and incubated for 10 minutes. A 10 1t aliquot of granulocyte suspension (containing lOx 106 granulocytes/ml unless specified) was then added to the centre of the serum drop and incubated at room temperature, whereafter a cover slip was added and sealed with nail polish. Maximum clustering was reached after incubation for one minute, and no evidence of resolving cell clusters was seen up to five minutes. An SLEflares (n=20) were associated with higher neutrophil clustering activity than were minorflares (n= 10) (p<0 05). group.bmj.com on July 5, 2017 -Published by http://ard.bmj.com/ Downloaded from (n= 11) had significantly higher neutrophil clustering activity (median 0-9, range 0 43 to 2-1) than patients with normal leucocyte counts (median 0-28, range -0 04 to 1-44; p<001). A similar but less marked difference was found in patients with a neutrophil count of <3x109/l (n=11, neutrophil clustering activity median 0-9, range 0-43 to 2-1) than in patients with a greater number of neutrophils (median 0-28, range -0-04 to 1-%; p<001). Lymphocyte and platelet counts were not related to neutrophil clustering activity in these patients. When all patients with SLE were included no correlation was found between neutrophil clustering activity and total leucocyte, neutrophil, or lymphocyte count, but when only patients with active disease without glucocorticoid treatment were studied (n= 16) there was a significant correlation between neutrophil clustering activity and the number ofneutrophils (r,= -0-64, p<005) ( fig 5) and the total number of leucocytes (r,=0 63, p<0 05).
CIRCULATING IMMUNE COMPLEXES
Twenty nine of the 30 patients with active SLE had increased amounts of Clq binding circulating immune complexes (median 875 ,ug/ml, range <50-2300). Patients with major flares had higher concentrations of complexes than those with minor flares (p<005). A weak correlation was found between Clq binding assay and neutrophil clustering activity (rs=0 4, p<005 Figure 6 shows the sequential follow up of two patients with high neutrophil clustering activity. making its use for increasing the aggregation response debatable, and casting doubt on the relation to in vivo situations. It is possible that the present assay measures aggregating serum factors other than those measured by assays using cytochalasin B.
Abramson et al8 found a particularly high neutrophil aggregating activity in serum samples from patients with CNS lupus, which suggests a relation with CNS vasculitis. Two of three patients with the highest neutrophil clustering activity in our study had hemianopia as evidence of cerebrovascular disease, and the third patient also had some evidence of CNS lupus (fig 6a) . As a group, however, patients with CNS manifestations did not differ from the remainder, a finding perhaps explained by the different pathogenetic mechanisms operating.
Leucergy-that is, leucocyte agglomeration in citrated whole blood-has been studied by Berliner et al. 7 In contrast with the findings in our study, he found increased leucergy in many rheumatic diseases and a response that correlated with erythrocyte sedimentation rate and disease activity. Different clustering/aggregating factors, perhaps related to the presence of platelets, may be operative in the leucergy test.
In conclusion, this simple and reproducible assay for neutrophil clustering in human sera may be a valuable tool in the study of 
